Protective Role of Toll-like Receptor 4 during the Initiation Stage of Cutaneous Chemical Carcinogenesis

Nabiha Yusuf,1,2 Tahseen H. Nasti,1 J. Alan Long,1 Mohammed Naseemuddin,1 Alan P. Lucas,1 Hui Xu,1 and Craig A. Elmets1,2

1Department of Dermatology and Skin Diseases Research Center, University of Alabama at Birmingham; 2Veteran Affairs Medical Center, Birmingham, Alabama

Abstract

Toll-like receptors (TLR) activate multiple steps in inflammatory reactions in innate immune responses. They also activate signals that are critically involved in the initiation of adaptive immune responses. Many tumorigenic chemicals have been associated with endotoxin hypersensitivity mediated through TLR4. To determine the role of TLR4 in cutaneous skin carcinogenesis, we treated TLR4-deficient C3H/HeJ mice and the TLR4-normal C3H/HeN mice with the carcinogenic polyaromatic hydrocarbon 7,12-dimethylbenz(a)anthracene (DMBA). TLR4-deficient C3H/HeJ mice developed more tumors relative to the TLR4-normal C3H/HeN mice. Both C3H/HeN and C3H/HeJ mice developed a T-cell–mediated immune response to topically applied DMBA. Interestingly, the cell-mediated immune response was mediated by IFN-γ in C3H/HeN mice and by interleukin (IL)-17 in C3H/HeJ mice. Moreover, C3H/HeN mice had elevated circulating levels of IFN-γ following topical application of DMBA, whereas IL-17 was elevated in C3H/HeJ mice. The results of this study indicate that TLR4 plays an important role in the prevention of DMBA skin tumorigenesis and that this is associated with differences in the T-cell subtype activated. Efforts to divert the cell-mediated immune response from one that is IL-17 mediated to one that is IFN-γ mediated may prove to be beneficial in the prevention of DMBA-induced cutaneous tumors. [Cancer Res 2008;68(2):615–22]

Introduction

Toll-like receptors (TLR), a family of molecules that recognize conserved pathogen-associated molecular patterns, have emerged as a key component of the innate immune system. Their ligation leads to the induction of inflammatory responses by transcriptional activation of cytokine, chemokine, and adhesion molecule genes. Mammalian TLRs consist of at least 13 different membrane proteins collectively known as pattern recognition receptors. Some of them are expressed at the cell surface, whereas others are located on the membrane of endocytic vesicles or other intracellular organelles. Individual TLRs differ in their ligand specificity, expression patterns, and signal transduction pathways that they activate (1–3).

Recognition of endogenous ligands by TLRs is now thought to have an important role in the regulation of inflammation, both in infectious and noninfectious diseases (4). This is due in part to the fact that a subset of TLR-induced signals is critically involved in the control of adaptive immune responses (5). There is experimental evidence to suggest that, in some instances, neoplasms may also exploit TLR signaling pathways to advance cancer progression. It has been shown that inflammatory processes promote (rather than initiate) carcinogenesis in a non–cell-autonomous fashion (6). At sites of inflammation, cytokines, chemokines, and matrix-degrading enzymes are released in a persistent unregulated manner predominantly by cells of the innate immune system and these molecules enhance angiogenesis, invasiveness, and survival of premalignant and neoplastic cells (7).

Polyaromatic hydrocarbons, such as 7,12-dimethylbenz(a)anthracene (DMBA), have been used extensively to investigate the mechanisms by which chemicals cause cancer. Although the immune-mediated destruction of the malignant cells is well established, the role of the innate immune system in the development of epithelial malignancies and its potential for immunoprevention has received much less attention (8). The presence of TLRs on resident skin cells may assist in mounting a rapid and efficient host defense against early events in the development of these neoplasms. TLRs are expressed on epidermal cells, including keratinocytes (9, 10), Langerhans cells (11), and dermal mast cells (12). TLRs expressed on human and murine epidermal cells are functional and play an important role in innate immunity in the skin (11, 13).

We have previously reported that application of DMBA to the skin of selected strains of mice results in the development of antigen-specific allergic contact hypersensitivity and that mice in which such a response is present are resistant to tumor development when subjected to a chemical skin carcinogenesis protocol (14). This has lead to the hypothesis that, in addition to the host immune response against chemically induced tumors, there are immunologic influences that target the chemicals that cause the tumors. In other words, we have proposed that contact hypersensitivity to DMBA has a protective effect on skin carcinogenesis by reducing the number of mutant cells that can go on to become tumors.

Because TLRs have an influence on adaptive immune responses and many tumorigenic chemicals have been associated with endotoxin hypersensitivity mediated through TLR4, the purpose of this study was to determine whether TLR4 was involved in DMBA cutaneous carcinogenesis.

Materials and Methods

Animals and reagents. Female C3H/HeN mice were purchased from Charles River Laboratories. Female C3H/HeJ mice were obtained from The Jackson Laboratory. Mice used for experiments were 6 to 8 weeks of age. All animal procedures were performed according to NIH guidelines under
protocols approved by the Institute Animal Care and Use Committee of the University of Alabama at Birmingham.

Hybridoma line XMG1.2 (anti-IFN-γ) was from the American Type Culture Collection and antibody was purified from culture supernatants by affinity chromatography. Normal rat IgG was purchased from Rockland Immunochemicals. Mouse recombinant granulocyte macrophage colony-stimulating factor (GM-CSF), anti-CD3e, streptavidin-phycoerythrin-Cy5, and anti-CD31 (platelet/endothelial cell adhesion molecule) antibodies were purchased from PharMingen and monoclonal rat anti-mouse interleukin (IL)-17 antibody (TC11-18H10) was acquired from Southern Biotechnology. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMBA, and IL-4 were purchased from Sigma Chemical Co.

Sensitization and elicitation of contact hypersensitivity. The induction and elicitation of contact hypersensitivity in mice were carried out as described (15). Briefly, C3H/HeN and C3H/HeJ mice were sensitized with 100 μL of 0.1% DMBA (w/v in acetone) on their shaved and depilated abdomen on day 0. The mice were challenged on the ear 5 days later. Contact hypersensitivity was measured daily for 5 days beginning 24 h after challenge. To detect the roles of IL-17 and IFN-γ in the elicitation of contact hypersensitivity, mice were injected i.p. with either anti-IL-17 antibody (200 μg) or anti-IFN-γ antibody (400 μg) on days +4 and +5 as described earlier (16). To assess the cytokine profile, mice were sensitized with DMBA (0.1% w/v in acetone) on day 0. On day +5, mice were sacrificed and lymph node cell suspensions were prepared by gentle pressure through a wire mesh screen. Cells were then washed and placed in 96-well culture plates at a concentration of 2 × 10^5/200 μL in complete medium. Before addition of cells, the plates were coated with anti-CD3 antibody as described previously (17). After an incubation period of 48 h, media were harvested and assayed for cytokine concentrations.

ELISA for cytokine production. Cytokine concentrations in culture medium from bone marrow–derived dendritic cells (BMDC), skin and tumor lysates, and serum were measured using cytokine-specific ELISA using commercial kits from Invitrogen according to the manufacturer’s instructions.

Skin tumorigenesis. We used a standard DMBA complete carcinogenesis protocol for this study. DMBA (400 nmol, w/v in acetone) was painted weekly on the shaved and depilated dorsal skin of C3H/HeN and C3H/HeJ mice (15 mice per panel). Mice were evaluated weekly for tumors. Only tumors that had attained a size of ≥1 mm and were present for ≥2 weeks were counted.

Generation of BMDCs. BMDCs were prepared from C3H/HeN and C3H/HeJ mice as described previously (18) with some modifications. Briefly, bone marrow cells were isolated from femurs and tibias. The cells were incubated in RPMI 1640 with a cocktail of antibodies against Ia, CD45R/B220, Lyt-2, and GK1.5 (2 μg/10^6 cells) on ice for 1 h and washed once with HBSS after lysis of RBCs. Different cellular populations were removed from suspension by antibody-mediated depletion using sheep anti-rat IgG dynabeads according to the manufacturer’s instructions. Cells were washed once with HBSS and cultured in 10% FCS-RPMI 1640 supplemented with recombinant mouse GM-CSF (10 ng/mL) and IL-4 (10 ng/mL) in six-well plates (5 × 10^6 per well). On day 6, half of the medium was replaced with fresh medium and cells were incubated in culture with polymyxin B (10 μg/mL) to prevent

![Figure 1.](chart.png)
lipopolysaccharide (LPS) contamination. After 24 h of culture at 37°C in the presence of 5% CO₂, culture media were collected and evaluated for cytokines.

**Preparation of tissue lysates.** The back skin samples were scraped of s.c. fat and washed with PBS. Both skin and tumors were collected from at least four mice and homogenized in ice-cold lysis buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 20 mmol/L NaF, 100 mmol/L Na₃VO₄, 5% NP-40, 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride (pH 7.4)] with freshly added protease inhibitor cocktail (Protease Inhibitor Cocktail, Sigma Chemical). The homogenate was then centrifuged at 14,000 x g for 25 min at 4°C and the supernatant (total cell lysate) was collected, aliquoted, and stored at −80°C. The protein content in the lysates was measured with a detergent-compatible Bio-Rad assay according to the manufacturer’s protocol.

**Proliferation assay in tumor cells.** The proliferative potential of tumor cells obtained from TLR-deficient C3H/HeJ and C3H/HeN mice was assessed using the MTT assay as described previously (19). Tumor cells were cultured as described by Maeda et al. (20) with some modifications. Briefly, tumor pieces of <2 mm³ in size were seeded into culture plates and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% MEM nonessential amino acid, and 1% antibiotic/penicillin-streptomycin solution. When the cultures had reached 80% confluence, the adherent cells were detached with 0.1% trypsin/0.05% EDTA (Life Technologies) and used for subsequent passage. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO₂. Cells were harvested and seeded in triplicate into 96-well plates at a density of 2 x 10⁴ per well. At 0, 1, 2, or 3 days after seeding, MTT solution was added to each well followed by incubation for 2 h at 37°C. After incubation, DMSO was added to each well. Spectrophotometric absorbance of each sample was measured at 540 nm using a microplate reader (Bio-Rad).

**Assessment of expression of vascular endothelial cell antigen, CD31.** Immunostaining for CD31 was done on frozen tumor sections from C3H/HeJ and C3H/HeN mice. Briefly, frozen sections (5 μm thick) were fixed in cold acetone and nonspecific binding sites were blocked by immersing the sections in Tris-HCl buffer containing 5% goat serum and bovine serum albumin (0.5% w/v). The sections were then incubated with monoclonal antibodies specific for CD31 for 1 h. Antibody binding was detected by subsequent incubation of sections with streptavidin-phycocerythrin-Cy5 secondary antibody for 1 h. After washing, the sections were counterstained with Hoechst 33342, which stains nuclei. The intensity of the staining was evaluated using a microscope equipped for immunofluorescence analysis.

**Statistical analysis.** The differences between experimental groups for contact hypersensitivity and cytokine ELISAs were analyzed using the Student’s t test. The Fisher’s exact test was used for analysis of the tumors per group and the percentage of mice with tumors. In all cases, a P < 0.05 was considered significant.

**Results**

Contact hypersensitivity in TLR4-deficient mice is mediated mainly by IL-17. Topical application of the carcinogenic polyaromatic hydrocarbon DMBA results in the development of...
of antigen-specific contact hypersensitivity (15). To determine whether TLR4 influences contact hypersensitivity to DMBA, panels of C3H/HeN and C3H/HeJ mice were sensitized to that agent and the contact hypersensitivity response in the two strains was compared. Both strains developed contact hypersensitivity to DMBA-induced skin tumors. Tumor cells were obtained from DMBA-sensitized mice and subjected to a MTT assay immediately and 1, 2, or 3 d after having been placed in culture as described in Materials and Methods. Proliferative potential of tumor cells is expressed in terms of absorbance of each sample. The proliferative capacity was higher (*, \( P < 0.05 \)) in tumor cells obtained from C3H/HeJ mice when compared to naive C3H/HeN mice. Columns, mean of triplicate cultures; bars, SD. Each experiment was repeated thrice.

Figure 3. TLR4-deficient C3H/HeJ mice are more susceptible to DMBA-induced carcinogenesis than TLR-normal C3H/HeN mice. Mice were subjected to a complete cutaneous carcinogenesis protocol (15 mice per panel) using DMBA as described in Materials and Methods. A, the number of tumors per group was plotted as a function of the number of weeks on the test. There were significantly more tumors in C3H/HeJ mice (*, \( P < 0.05 \)) than in C3H/HeN mice. B, the percentage of mice with tumors was plotted as a function of the number of weeks of the test. By the 7th week, 100% of C3H/HeJ mice had tumors compared with 20% of C3H/HeN mice. C, tumors from C3H/HeJ mice were significantly larger (*, \( P < 0.05 \)) in volume than tumors from C3H/HeN mice. D, proliferative capacity of tumor cells from DMBA-induced skin tumors. Tumor cells were obtained from DMBA-induced tumors from C3H/HeN or C3H/HeJ mice and subjected to a MTT assay immediately and 1, 2, or 3 d after having been placed in culture as described in Materials and Methods. Proliferative potential of tumor cells is expressed in terms of absorbance of each sample. The proliferative capacity was higher (*, \( P < 0.05 \)) in tumor cells obtained from C3H/HeJ mice when compared to naive C3H/HeN mice. Columns, mean of triplicate cultures; bars, SD. Each experiment was repeated thrice.

of antigen-specific contact hypersensitivity (15). To determine whether TLR4 influences contact hypersensitivity to DMBA, panels of C3H/HeN and C3H/HeJ mice were sensitized to that agent and the contact hypersensitivity response in the two strains was compared. Both strains developed contact hypersensitivity to DMBA and the magnitude of the ear swelling response in the two strains was comparable (\( P > 0.05 \); Fig. 1A and B).

Effector T cells for contact hypersensitivity to other haptens have been shown to produce IFN-\( \gamma \) and IL-17 (16, 17). To determine the influence of TLR4 on the cytokine pattern of the effector T cells, DMBA-sensitized lymph node cells were isolated and placed in culture in anti-CD3-coated plates. Media were removed 48 h later and examined for secreted IFN-\( \gamma \) and IL-17 by ELISA. Cells from C3H/HeN sensitized mice produced significantly greater amounts of IFN-\( \gamma \) (\( P < 0.05 \)) than C3H/HeJ mice (Fig. 1C). In contrast, the amount of secreted IL-17 produced by lymph node cells from DMBA-sensitized C3H/HeN mice was not significantly greater than that produced by cells from naive mice. In contrast, there was a marked increase in IL-17 (\( P < 0.05 \)) secretion by lymph node cells from DMBA-sensitized C3H/HeJ mice (Fig. 1D). These results indicated that inactivation of TLR4 shifts that balance from IFN-\( \gamma \)-producing cells to those that produce IL-17.

To examine the importance of IL-17 or IFN-\( \gamma \) in vivo in DMBA contact hypersensitivity, C3H/HeN and C3H/HeJ mice were sensitized to DMBA and then treated with either anti-IL-17, anti-IFN-\( \gamma \) antibodies, or rat IgG (as a control) before challenge. The contact hypersensitivity response was significantly inhibited in C3H/HeN mice (\( P < 0.05 \)) when treated with anti-IFN-\( \gamma \) antibody (Fig. 2A). In contrast, treatment of C3H/HeJ mice, which are deficient in TLR4, with neutralizing anti-IFN-\( \gamma \) antibody (400 \( \mu \)g/mouse) did not show a significant inhibitory effect (Fig. 2B). On the other hand, treatment with anti-IL-17 (200 \( \mu \)g/mouse) had no effect on DMBA contact hypersensitivity in C3H/HeN mice (Fig. 2C), whereas in C3H/HeJ mice the contact hypersensitivity response was significantly inhibited (\( P < 0.05 \)) compared with controls treated with normal rat IgG at the same dose (Fig. 2D).

TLR4-deficient mice are more susceptible to cutaneous DMBA carcinogenesis. The role of TLR4 in DMBA cutaneous carcinogenesis was next investigated by comparing C3H/HeN and C3H/HeJ mice for tumor development. The two strains were
subjected to a complete carcinogenesis protocol in which DMBA was applied weekly to the skin. The number of tumors was significantly greater \( (P < 0.05) \) in C3H/HeJ mice compared with C3H/HeN mice (Fig. 3A). Similar results were obtained when the data were evaluated as the cumulative number of tumors and the number of tumors per tumor-bearing mouse (data not shown). Although all animals in both strains eventually developed tumors with this protocol, they arose more rapidly in TLR4-deficient C3H/HeJ mice. For example, by week 7, 100% of C3H/HeJ mice had developed tumors, whereas only 20% of C3H/HeN mice had tumors, and these differences were significant \( (P < 0.05; \text{Fig. 3B}) \).

The tumors from C3H/HeJ mice grew progressively and showed a significant \( (P < 0.05) \) increase in volume compared with tumors from C3H/HeN mice (Fig. 3C).

**Tumor cell lines from TLR4-deficient mice show an increase in proliferative capacity.** To study the growth behavior of the DMBA-induced tumors, tumor specimens were obtained from both C3H/HeJ and C3H/HeN mice. Tumor pieces of <2 mm\(^3\) were seeded into culture plates and cultured as described in Materials and Methods. When the cultures had reached 80% confluence, the adherent cells were detached with 0.1% trypsin/0.05% EDTA and used for subsequent passage. To determine their capacity to proliferate, cell lines were subjected to a MTT proliferation assay, which was done immediately or at 1, 2, and 3 days after seeding. In all samples tested, the proliferative capacity was higher \( (P < 0.05) \) in cell lines obtained from DMBA-treated C3H/HeJ mice compared with cell lines developed in C3H/HeN mice (Fig. 3D).

**TLR4-deficient mice express higher levels of IL-17 and lower levels of IFN-\(\gamma\) after DMBA carcinogenesis.** Because IFN-\(\gamma\) and IL-17 have an influence on development of the DMBA contact hypersensitivity response, we also assessed their role during DMBA-induced tumor development. Tumor, skin, and blood samples were collected from C3H/HeJ and C3H/HeN mice after 25 weeks on the DMBA skin tumorigenesis protocol. At 25 weeks, serum from these mice showed a slight but significant increase in IFN-\(\gamma\) \( (P < 0.05) \) in C3H/HeN mice compared with C3H/HeJ mice. Conversely, there was a significant decrease in IL-17 \( (P < 0.001) \) production in C3H/HeN mice compared with C3H/HeJ mice (Fig. 4A and C). These differences in cytokine levels were accentuated in tumor lysates. C3H/HeN mice showed a much greater increase in IFN-\(\gamma\) \( (P < 0.001) \) and a greater reduction in IL-17 \( (P < 0.05) \) than in C3H/HeJ mice (Fig. 4B and D). The greater differences in tumor cytokine levels likely reflect the selective accumulation of T cells producing IFN-\(\gamma\) and IL-17 in tumors from C3H/HeN and C3H/HeJ mice, respectively.

**TLR4-deficient mice express higher levels of IL-23 and lower levels of IL-12 after DMBA carcinogenesis and are more prone to angiogenesis.** BMDCs from DMBA-treated C3H/HeJ mice secreted smaller amounts of IL-12 \( (P < 0.05) \) and more IL-23 \( (P < 0.05) \) than C3H/HeN mice (Fig. 5A and B). Similar patterns of circulating cytokines IL-12 \( (P < 0.05) \) and IL-23 \( (P < 0.05) \) were found in the serum of DMBA-treated C3H/HeN and C3H/HeJ mice (Fig. 5C and D).

Figure 4. Tumor-bearing TLR4-deficient C3H/HeJ mice produce less IFN-\(\gamma\) and more IL-17 than TLR4-normal C3H/HeN tumor-bearing mice. Cytokines were measured in serum, and skin and tumor lysates from mice after having been subjected to a DMBA cutaneous carcinogenesis protocol for 25 wk. C3H/HeN mice showed higher levels of IFN-\(\gamma\) in their serum \( (A) \) and skin and tumor lysates \( (B) \) compared with C3H/HeJ mice. C3H/HeJ mice showed higher levels of IL-17 in their serum \( (C) \) and skin and tumor lysates \( (D) \); \( *, P < 0.05 \) compared with C3H/HeJ mice. Columns, mean of panels containing four mice per group; bars, SD. Each experiment was repeated twice with similar results. \( *, P < 0.05; **, P < 0.001. \)
Because TLR4-deficient C3H/HeJ mice had higher levels of IL-17 in their serum and tumors and C3H/HeN mice had greater amounts of IL-12 and IFN-γ, we were interested in determining whether angiogenic growth factors vascular endothelial growth factor (VEGF), macrophage inflammatory protein-2 (MIP-2), and keratinocyte chemoattractant (KC) levels lead to an increase in tumor angiogenesis in C3H/HeJ mice than in C3H/HeN mice. We observed that this was the case; following treatment with DMBA, VEGF ($P < 0.05$), MIP-2 ($P < 0.001$), and KC ($P < 0.05$) levels in tumor lysates were significantly higher in C3H/HeJ mice than in C3H/HeN mice (Fig. 6A–C).

We next assessed the extent of neovascularization of the tumors by examination of the expression of CD31, which is known to contribute to the formation of new vasculature and is used as a biomarker of angiogenesis (21). The intensity of the CD31 immunofluorescent staining was increased in the DMBA-induced tumors of C3H/HeJ mice tumors compared with C3H/HeN mice (Fig. 6D).

**Discussion**

Positional cloning of the locus responsible for LPS hyporesponsiveness in C3H/HeJ mice and generation of TLR4 knockout mice have shown that TLR4 is essential for LPS signaling (22). In addition to activation by LPS signaling, TLR4 is also associated with signaling by many environmental chemicals, many of which are tumorigenic (23). Stimulation of TLRs by various ligands leads to signaling pathways that activate not only innate but also adaptive immunity by antigen-presenting cell (APC)-dependent or APC-independent mechanisms (5).

In previous studies from our laboratory, it has been shown that topical application of the carcinogenic polyaromatic hydrocarbon DMBA results in the development of antigen-specific contact hypersensitivity (15). We had also proposed that the allergic contact hypersensitivity response to DMBA that occurs in some strains of mice serves to protect those animals against the carcinogenic activities of that compound. This hypothesis is based in part on observations that there is an inverse relationship between cell-mediated immunity to DMBA and the number of tumors that develop in C3H/HeN and C3H.SWmice, MHC congenic mice (14). We have also observed that mice deficient in CD4$^+$ T cells are resistant to the development of DMBA-induced skin tumors than normal mice, whereas mice deficient in CD8$^+$ T cells are more likely to develop them. The results of these studies support that hypothesis with modifications. Although the magnitude of the contact hypersensitivity response in both C3H/HeN and C3H/HeJ mice was equivalent, C3H/HeJ mice were more susceptible to DMBA skin tumorigenesis, whereas C3H/HeN mice were not. However, the DMBA contact hypersensitivity response in C3H/HeN mice was mediated primarily by IFN-γ–producing T cells and in C3H/HeJ mice by IL-17–producing T cells.

---

3 N. Yusuf et al., unpublished data.
Based on these findings, a more appropriate hypothesis for the relationship between T-cell immunity to DMBA and the initiation of DMBA skin carcinogenesis is that mice that develop a cell-mediated immune response to DMBA in which the effector cells are IFN-γ–producing T cells will be resistant to DMBA skin tumorigenesis but those that have IL-17 effector T cells or do not develop a contact hypersensitivity response at all will be susceptible to the carcinogenic activities of that agent.

Our results extend those observations by providing evidence that TLR4 determines the type of effector T cell that is generated following topical application of hapten. An intact TLR4 signaling pathway results in IFN-γ–producing effector T cells, whereas a defect in the TLR4 signaling pathway leads to the generation of IL-17–producing effector T cells. These two types of effector T cells have distinct activities. Although both are effective at producing DMBA contact hypersensitivity, only the IFN-γ–producing T cells confer resistance to DMBA tumorigenesis. An obvious question is whether the controlling role that TLR4 has in determining the types of effector T cells that develop applies to other contact allergens. Our preliminary studies indicate that it does. Contact hypersensitivity to dinitrofluorobenzene also occurs in both C3H/HeN and C3H/HeJ mice and is mediated primarily by IL-17 cells in C3H/HeJ mice but by cells that produce IFN-γ in C3H/HeN mice (data not shown). Effector T cells for contact hypersensitivity to other haptens have been shown to produce IFN-γ and IL-17 (16, 17).

The process by which TLR4 leads to the preferential activation of IFN-γ–producing T cells is apt to be a multistep process. We observed that IL-12 levels were much greater (P < 0.05) in serum of C3H/HeN than in C3H/HeJ mice. IL-12 has been shown to encourage the development of IFN-γ T cells. On the other hand, IL-23 is required for IL-17–producing T cells (24, 25). Thus, TLR4–induced suppression of IL-23 and the unimpeded production of IL-12 is likely to be a step in this process. IL-17 has been shown to increase the growth of several different types of tumors (24, 26–28). It has been proposed that this is due at least in part to its proangiogenic effects (24, 27). On the other hand, IL-12 and IFN-γ, which were produced in greater amounts in C3H/HeN mice, have antiangiogenic properties. IL-17 up-regulates elaboration of various proangiogenic factors and modulates production of KC, MIP-2, and VEGF by fibroblasts. IL-17 might be a potential contributor to the inflammatory angiogenesis via induction of proangiogenic factors by stromal fibroblasts (29).

If it is true that IFN-γ–producing T cells are important effector cells for DMBA contact hypersensitivity and those cells are involved in reducing the development of DMBA-induced tumors, then it may be possible to use this information to develop methods that augment the induction of IFN-γ–producing T cells at the expense of IL-17–producing effector T cells and regulatory T cells that have a permissive role of chemical carcinogenesis.

Acknowledgments

Received 9/7/2007; revised 10/26/2007; accepted 11/7/2007.

Grant support: NIH grant P30 AR050948 (C.A. Elmets), Veterans Administration Merit Review Award 18-103-02 (C.A. Elmets), and Department of Defense.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Figure 6. TLR4 deficiency promotes angiogenesis. Angiogenic factors VEGF, MIP-2, and KC were measured in tumor lysates after 25 wk from mice placed on a DMBA cutaneous carcinogenesis protocol. TLR4-deficient C3H/HeJ mice showed significantly higher levels of VEGF (A), MIP-2 (B), and KC (C) compared with TLR4-normal C3H/HeN mice. Columns, mean of four mice per group; bars, SD. Each experiment was repeated thrice. D, the expression level of CD31 in DMBA-induced tumors was greater in C3H/HeJ mice compared with C3H/HeN mice. Samples of tumors were examined for CD31 fluorescence staining. Representative photomicrographs are shown from experiments conducted in tumor samples from at least five mice in each group. Identical patterns were observed in all of the tumors examined. CD31-positive staining is indicated by bright pink fluorescence. Bar, 50 μm. * P < 0.05; ** P < 0.001.

References

Correction: TLR4 in Cutaneous DMBA Carcinogenesis

In the article on TLR4 in cutaneous DMBA carcinogenesis in the January 15, 2008 issue of Cancer Research (1), “IFN-17” in Figs. 1D, 4C, and 4D should read as “IL-17”.

Protective Role of Toll-like Receptor 4 during the Initiation Stage of Cutaneous Chemical Carcinogenesis


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/2/615

Cited articles
This article cites 29 articles, 11 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/2/615.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/2/615.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.